title: Effects of cyclosporin A upon humoral and cellular immune parameters in insulin-dependent diabetes mellitus type I: a long-term follow-up study.
abstract: Patients who had been included in a randomized double-blind placebo-controlled trial on the efficacy of cyclosporin A (CyA) in producing remissions in insulin-dependent diabetes mellitus (IDDM) type I were investigated for humoral and cellular immunologic parameters. Whereas metabolic derangement before the initiation of insulin treatment led to small but significant decreases in the percentage of CD4-positive lymphocytes as well as of the activity of natural killer (NK) cells and antibody-dependent cellular cytotoxicity (ADCC), the administration of CyA did not influence any of the immunologic parameters tested, which included proliferative lymphocyte responses to mitogens and alloantigens and serum concentrations of immunoglobulins G, A and M. Thus NK cell activity, ADCC as well as the percentage of CD4-positive lymphocytes returned to normal levels in parallel with the normalization of glycosylated haemoglobin (HbAlc), but were not further influenced in their course by the administration of CyA, as compared with patients receiving placebo. Interferon-induced augmentation of NK cell activity did not differ between patients with IDDM on placebo and those under CyA therapy. All other investigated parameters also remained unchanged during the time of CyA therapy. We conclude that metabolic derangement leads to a reversible disturbance of certain cellular immune functions, but their normalization achieved by insulin treatment and their further course remains uninfluenced by the administration of CyA.
authors.affiliation: 2nd Department of Medicine, Vienna University Hospital, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Müller
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
authors.forename: W
authors.initials: W
authors.lastname: Kalinowski
authors.forename: H
authors.initials: H
authors.lastname: Wolf
authors.forename: J W
authors.initials: JW
authors.lastname: Mannhalter
authors.forename: G
authors.initials: G
authors.lastname: Aschauer-Treiber
authors.forename: D
authors.initials: D
authors.lastname: Klösch-Kasparek
authors.forename: S
authors.initials: S
authors.lastname: Gaube
authors.forename: M M
authors.initials: MM
authors.lastname: Eibl
authors.forename: G
authors.initials: G
authors.lastname: Schernthaner
mesh_terms: D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification; D008297:Male; D011897:Random Allocation
chemical_list: D003524:Cyclosporins; D006442:Glycated Hemoglobin; D007136:Immunoglobulins